Limagne, Emeric

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies

Oster, P., Vaillant, L., Riva, E., McMillan, B., Begka, C., Truntzer, C., Richard, C., Leblond, M. M., Messaoudene, M., Machremi, E., et al. (2022) · Gut

Cancer Immunotherapy and BiomarkersHelicobacter pylori-related gastroenterology studies

Cited by 176

IRF8‐dependent Molecular Complexes Control the Th9 Transcriptional Program

Humblin, E., Thibaudin, M., Chalmin, F., Derangère, V., Limagne, E., Richard, C., Flavell, R. A., Chevrier, S., Ladoire, S., Berger, H., et al. (2017) · Nature Communications

T-cell and B-cell ImmunologyPsoriasis: Treatment and Pathogenesis

Cited by 67

Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial

Ghiringhelli, F., Chibaudel, B., Taieb, J., Bennouna, J., Martin-Babau, J., Fonck, M., Borg, C., Cohen, R., Thibaudin, M., Limagne, E., et al. (2020) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 40